Financials
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|
STVN Catalyst Timeline
Dated clinical, regulatory and corporate events for Stevanato Group S.p.A.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Stevanato Group S.p.A.
Past FDA Catalysts and PDUFA Decisions
How STVN actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| No matching catalysts | ||||||
Drug Pipeline Intelligence
No drug pipeline
Stevanato Group S.p.A. is a medical device company. The clinical trials it takes part in test other companies' drugs, so it has no drug pipeline of its own to score.
Clinical Trial Results
Readouts, endpoints and source filings for every STVN program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| FEDERICI WILLIAM JDirector | Buy | 20,000 46,991 held | $13.72 | 11/09/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in STVN
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| TRI LOCUM PARTNERS LP | 2 % (11.1 %) | 8.57 M | 332.91 K | 89.5% ( 157.23 K) |
Ownership Trends
STVN Short Interest
Shares sold short, counted twice a month.
Options Data
Option Volume
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
Competitive positioning
How STVN ranks across every disease it competes in
STVN News
Stevanato Group to Participate in Upcoming Investor Conferences
Stevanato Group announced participation in the Jefferies Global Healthcare Conference in London from November 16 to 19, 2026. The company will also attend two other upcoming investor events. This engagement allows management to discuss business updates with the investment community.
Read more →Stevanato Group Delivers 8% Revenue Growth for the Third Quarter of Fiscal 2026
Stevanato Group reported an 8% revenue increase to €326.1 million for Q3 2026, driven by growth in its Biopharmaceutical and Diagnostic Solutions Segment. The company maintained its fiscal year guidance, expecting revenue between €1.260 billion and €1.280 billion. However, it noted a decline in the Engineering Segment and anticipated lower GLP-1 revenues affecting future growth.
Read more →Stevanato Group and Aptar Pharma Collaborate to Help Accelerate Pre-Filled Syringe System Selection
Stevanato Group and Aptar Pharma have announced a collaboration to enhance the evaluation of pre-filled syringe systems. This partnership will provide critical system-level data to help pharmaceutical companies make informed packaging decisions for sensitive biologics. The collaboration focuses on improving the performance of high-value syringe systems and elastomer components, addressing challenges in drug development.
Read more →Stevanato Group to Report Third Quarter 2026 Financial Results on November 3, 2026
Stevanato Group S.p.A. will announce its financial results for the third quarter of 2026 on November 3, 2026. A conference call and webcast will follow at 8:30 a.m. (EDT) to discuss these results. Participants can pre-register for easier access to the call.
Read more →Ensera launches alliance network with SHL Medical, Stevanato Group, Ypsomed, Argonaut and American Injectables
Ensera has launched the Ensera Alliance Network, which includes SHL Medical, Stevanato Group, Ypsomed, Argonaut Manufacturing Services, and American Injectables. This network aims to simplify the commercialization of drug-device combination products by improving coordination among suppliers. The initiative seeks to reduce risks and accelerate the transition to commercial supply for pharmaceutical companies.
Read more →Stevanato Group to Participate in Two Upcoming Investor Conferences
Stevanato Group S.p.A. (NYSE: STVN) has announced its participation in two significant investor conferences. The first will be held on September 15 at the Morgan Stanley Annual Global Healthcare Conference in New York, followed by the BofA Global Healthcare Conference on September 22. These events aim to strengthen investor relations and showcase the company's offerings.
Read more →Stevanato Group Delivers 8% Revenue Growth for the Second Quarter of Fiscal 2026
Stevanato Group S.p.A. reported an 8% revenue growth for the second quarter of fiscal 2026, reaching €302.0 million. A significant portion of this revenue, 45%, came from high-value solutions. The company also noted an increase in its gross profit margin, indicating strong financial performance compared to the previous year.
Read more →Liraglutide Combination Products Incorporating Stevanato Group's Alina® Pen Injector Received Marketing Authorizations in Multiple European Countries
Stevanato Group S.p.A. announced that its liraglutide-based combination products, utilizing the Alina® pen injector, have received marketing authorizations across several European countries. This development signifies a notable expansion for the company in the European pharmaceutical market. The authorizations pertain to finished combination products held by respective marketing entities.
Read more →Stevanato Group to Report Second Quarter 2026 Financial Results on August 4, 2026
Stevanato Group S.p.A. will release its financial results for Q2 2026 on August 4, 2026. The announcement includes details about a conference call and webcast scheduled for the same day at 8:30 a.m. (EDT). This event will provide insights into the company's performance and future outlook.
Read more →Stevanato Group Introduces Deora™, a Pen Injector for Subcutaneous Delivery in Diabetes and Weight Management
Stevanato Group has launched Deora™, a pen injector designed for subcutaneous delivery. This device targets diabetes and weight management, aiming to enhance patient experience. The introduction of Deora™ reflects the company's commitment to innovative healthcare solutions.
Read more →Stevanato Group Announces Results of Ordinary and Extraordinary Shareholders’ Meeting
Stevanato Group held an ordinary and extraordinary shareholders' meeting. The details of the results or decisions made during the meeting were not disclosed in the article. The announcement indicates ongoing corporate governance activities.
Read more →Stevanato Group Announces Results of Ordinary and Extraordinary Shareholders' Meeting All Resolutions Proposed to Shareholders Passed Piombino Dese, Italy, June 3rd, 2026. Stevanato Group S.p.A. (NYSE: STVN
Stevanato Group S.p.A. held its Ordinary and Extraordinary Shareholders' Meeting on June 3rd, 2026, in which all proposed resolutions were approved. Shareholders granted new authorizations for share purchases and amendments to the Company's By-laws to facilitate corporate rights and governance. A new Board of Directors was appointed, alongside the approval of PricewaterhouseCoopers S.p.A. as the external auditor for financial statements up to the end of 2028. Additionally, a dividend of EUR 0.054 was approved for each share.
Read more →Published on
Stevanato Group S.p.A. will hold its Ordinary and Extraordinary General Meeting of Shareholders on May 26, 2026, via teleconference. Shareholders holding ordinary shares on the Record Date have rights to attend and vote, while beneficial owners must follow specific procedures to record their votes. The meeting will cover the appointment of members to the Board of Directors among other agenda items, emphasizing adherence to the Company's Bylaws and relevant civil codes.
Read more →Q1 2026 Financial Results Safe Harbor Statement Forward-Looking Statements This presentation contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that ref
Stevanato Group's Q1 2026 financial results presentation includes forward-looking statements that caution about various risks and uncertainties affecting the company's future performance. Key concerns include potential interruptions in operations, the complexities of product offerings, intense competition for skilled employees, and geopolitical factors that could negatively impact business. The statements emphasize that actual results may differ materially from the predictions made due to these various risks.
Read more →Stevanato Group Delivers 7% Revenue Growth (10% at Constant Currency) for the First Quarter of Fiscal 2026 - The Company Maintains Fiscal 2026 Guidance -
Stevanato Group S.p.A. reported a 7% increase in revenue for the first quarter of 2026, reaching €273.6 million, supported by growth in its Biopharmaceutical and Diagnostic Solutions segment. The company's adjusted EBITDA margin improved to 23.9%, reflecting operational efficiencies. Despite revenue declines in the Engineering Segment and challenges with depreciation, Stevanato maintains its fiscal guidance for the year, anticipating total revenue between €1.26 billion and €1.29 billion. The CEO expressed confidence in the company's strategic investments and focus on high-value solutions.
Read more →Stevanato Group Delivers 7% Revenue Growth (10% at Constant Currency) for the First Quarter of Fiscal 2026
Stevanato Group reported a 7% revenue growth for Q1 2026, reaching €273.6 million, with high-value solutions accounting for 47% of total revenue. The Biopharmaceutical and Diagnostic Solutions segment drove this growth with a 13% increase. Despite a decline in the Engineering Segment, the company maintained its fiscal guidance for the year, expecting revenue between €1.26 billion and €1.29 billion.
Read more →Stevanato Group to Participate in Three Upcoming Investor Conferences
Stevanato Group is set to participate in three upcoming investor conferences. The details regarding the specific conferences and their dates were not provided in the article. This participation indicates the company's ongoing engagement with investors and stakeholders.
Read more →Stevanato Group to Report First Quarter 2026 Financial Results on May 7, 2026
Stevanato Group S.p.A. will release its financial results for Q1 2026 on May 7, 2026, at 6:30 a.m. EDT. A conference call and webcast will follow at 8:30 a.m. EDT, where management will discuss the results. Participants can pre-register for immediate access and will have the opportunity to ask questions during the call.
Read more →Stevanato Group to Participate in the KeyBanc Capital Markets Virtual Healthcare Forum
Stevanato Group S.p.A. will participate in the KeyBanc Capital Markets Virtual Healthcare Forum on March 17-18, 2026. The company is set to present on March 17 from 9:45 to 10:20 a.m. ET, with a live webcast available on its website. A replay of the event will be accessible for 90 days post-forum.
Read more →Stevanato Group Delivers 7% Revenue Growth (9% at Constant Currency) for Fiscal Year 2025, Including Record Revenue from High-Value Solutions and Expanded Margins
Stevanato Group reported a 7% revenue growth for fiscal year 2025, reaching €1.186 billion, with high-value solutions contributing significantly. The fourth quarter saw a 5% revenue increase, driven by strong performance in the Biopharmaceutical and Diagnostic Solutions Segment. The company anticipates continued growth in fiscal 2026, projecting revenue between €1.26 billion and €1.29 billion.
Read more →